Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study
European Journal of Cancer · 2026-11 · 248 · 117039
DOI: 10.1016/j.ejca.2026.117039 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Jason Valent und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoglobulin Light-chain Amyloidosis. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alexion Pharmaceuticals Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
- Clinical Development, Alexion, AstraZeneca Rare Disease, New Haven, CT, USA.
- Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Wilmington, DE, USA.
- Clinical Development, Alexion, AstraZeneca Rare Disease, London, UK.
- Fortrea, Inc., Durham, NC, USA.
Förderung
- Alexion Pharmaceuticals Inc
Zitieren
APA
Valent, J., Zonder, J., Swenson, E. S., Catini, J., Manwani, R., Ahuja, B., Khan, Z., & Liedtke, M. (2026). Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study. European Journal of Cancer, 248, 117039. https://doi.org/10.1016/j.ejca.2026.117039
Vancouver
Valent J, Zonder J, Swenson ES, Catini J, Manwani R, Ahuja B, et al. Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study. European Journal of Cancer. 2026;248:117039. doi:10.1016/j.ejca.2026.117039
BibTeX
@article{Valent2026,
author = {Valent, Jason and Zonder, Jeffrey and Swenson, E Scott and Catini, Julia and Manwani, Richa and Ahuja, Bhavna and Khan, Zilehuma and Liedtke, Michaela},
title = {Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117039},
doi = {10.1016/j.ejca.2026.117039}
}
EUVIMED